Clinical Trial: TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 >=50%

U.S., Dec. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07279402) titled 'TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 >=50%' on Dec. 01.

Brief Summary: This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell expression >=50% and no targetable mutations. The study aim to determine how atezolizumab performs in routine clinical practice with respect to survival, treatment response, and safety outcomes in this patient population in Turkiye.

Study Start Date: Sept. 15

Study Type: OBSERVATIONAL

Condition: NSCL...